Literature DB >> 26034401

Persistent and Recurrent Clostridium difficile Colitis.

Shola A Cole1, Thomas J Stahl2.   

Abstract

Clostridium difficile infection (CDI) is the most frequent cause of nosocomial diarrhea. It has become a significant dilemma in the treatment of patients, and causes increasing morbidity that, in extreme cases, may result in death. Persistent and recurrent disease hamper attempts at eradication of this infection. Escalating levels of treatment and novel therapeutics are being utilized and developed to treat CDI. Further trials are warranted to definitively determine what protocols can be used to treat persistent and recurrent disease.

Entities:  

Keywords:  BI/NAP1/027; fecal microbiota therapy; recurrent Clostridium difficile

Year:  2015        PMID： 26034401      PMCID： PMC4442717          DOI： 10.1055/s-0035-1547333

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN： 1530-9681


  15 in total

Review 1.  Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.

Authors:  Ethan Gough; Henna Shaikh; Amee R Manges
Journal:  Clin Infect Dis       Date:  2011-11       Impact factor: 9.079

Review 2.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

Review 3.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

4.  Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease.

Authors:  Matthew D Neal; John C Alverdy; Daniel E Hall; Richard L Simmons; Brian S Zuckerbraun
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

Review 5.  Best strategies in recurrent or persistent Clostridium difficile infection.

Authors:  Christine S Cocanour
Journal:  Surg Infect (Larchmt)       Date:  2011-07-18       Impact factor: 2.150

6.  Colonoscopic decompression and intubation of the cecum for Ogilvie's syndrome.

Authors:  W Groff
Journal:  Dis Colon Rectum       Date:  1983-08       Impact factor: 4.585

7.  Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea.

Authors:  Wallace J Wang; Sondra Gray; Cristina Sison; Sushma Arramraju; Bijo K John; Syed A Hussain; Sang H Kim; Preeti Mehta; Moshe Rubin
Journal:  Therap Adv Gastroenterol       Date:  2014-01       Impact factor: 4.409

Review 8.  The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review.

Authors:  John O'Horo; Nasia Safdar
Journal:  Int J Infect Dis       Date:  2009-01-30       Impact factor: 3.623

9.  Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.

Authors:  Kathleen M Mullane; Mark A Miller; Karl Weiss; Arnold Lentnek; Yoav Golan; Pamela S Sears; Youe-Kong Shue; Thomas J Louie; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

10.  Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.

Authors:  Iris Figueroa; Stuart Johnson; Susan P Sambol; Ellie J C Goldstein; Diane M Citron; Dale N Gerding
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079
View more
  8 in total

1.  Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion.

Authors:  Souwelimatou Amadou Amani; Tyler Shadid; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

2.  The (p)ppGpp Synthetase RSH Mediates Stationary-Phase Onset and Antibiotic Stress Survival in Clostridioides difficile.

Authors:  Astha Pokhrel; Asia Poudel; Kory B Castro; Michael J Celestine; Adenrele Oludiran; Alden J Rinehold; Anthony M Resek; Mariam A Mhanna; Erin B Purcell
Journal:  J Bacteriol       Date:  2020-09-08       Impact factor: 3.490

3.  Functional analysis of Clostridium difficile sortase B reveals key residues for catalytic activity and substrate specificity.

Authors:  Chia-Yu Kang; I-Hsiu Huang; Chi-Chi Chou; Tsai-Yu Wu; Jyun-Cyuan Chang; Yu-Yuan Hsiao; Cheng-Hsuan Cheng; Wei-Jiun Tsai; Kai-Cheng Hsu; Shuying Wang
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

4.  Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.

Authors:  Alexander G Vandell; Satoshi Inoue; Justin Dennie; Yasuo Nagasawa; Roohi Gajee; Joe Pav; George Zhang; Cynthia Zamora; Nobuhisa Masuda; Giorgio Senaldi
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection.

Authors:  Yuman Lee; Wai I Lim; Caitlyn I Bloom; Samantha Moore; Elizabeth Chung; Nino Marzella
Journal:  P T       Date:  2017-12

6.  THAs Performed Within 6 Months of Clostridioides difficile Infection Are Associated with Increased Risk of 90-Day Complications.

Authors:  Scott J Douglas; Ethan A Remily; Oliver C Sax; Sahir S Pervaiz; Evan B Polsky; Ronald E Delanois
Journal:  Clin Orthop Relat Res       Date:  2021-12-01       Impact factor: 4.176

7.  Effects of co-infection on the clinical outcomes of Clostridium difficile infection.

Authors:  Muhammad Shafiq; Hani Alturkmani; Yousaf Zafar; Vishal Mittal; Hafsa Lodhi; Waqas Ullah; Joseph Brewer
Journal:  Gut Pathog       Date:  2020-02-25       Impact factor: 4.181

8.  Recognition of extracellular DNA by type IV pili promotes biofilm formation by Clostridioides difficile.

Authors:  Leslie A Ronish; Ben Sidner; Yafan Yu; Kurt H Piepenbrink
Journal:  J Biol Chem       Date:  2022-09-03       Impact factor: 5.486
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.